Boston Therapeutics (BTHE) 0.6100 $BTHE
Boston Therapeutics Signs Agreement With Patheon to Manufacture Pharmaceutical-Grade BTI-320 Tablets
Marketwire - Wed May 07, 5:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a clinical stage developer of innovator compounds that address diabetes and inflammatory diseases using complex carbohydrate chemistry, along with its Hong Kong-based strategic partner Advance Pharmaceutical Company, have together signed an agreement with pharmaceutical manufacturing company Patheon Inc. to manufacture pharmaceutical-grade tablets of the company's lead product candidate BTI-320, a compound designed to reduce post-meal elevation of blood glucose.
Boston Therapeutics to manufacture lead blood glucose product candidate BTI-320 in partnership with Advance Pharmaceutical Company and Patheon
M2 - Tue May 06, 7:54AM CDT
Carbohydrate chemistry company Boston Therapeutics (OTCQB:BTHE) reported on Tuesday the launch of an agreement to manufacture its pharmaceutical-grade tablets of its lead product candidate BTI-320 in partnership with its Hong Kong-based strategic partner Advance Pharmaceutical Company and Patheon.
Boston Therapeutics to Present Late-Breaking Poster on Mechanism of Action for BTI-320 at AACE Annual Congress in Las Vegas on May 14-18
Marketwire - Tue Apr 29, 5:15AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a clinical stage developer of innovative compounds that address diabetes and inflammatory diseases using complex carbohydrate chemistry, will present a late-breaking poster relating to its lead product candidate, BTI-320, at the American Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific and Clinical Congress at the Paris Las Vegas Hotel in Las Vegas, Nevada, May 14-18.
Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Boston Therapeutics, Inc.
Marketwire - Thu Mar 27, 8:32AM CDT
Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO) on Boston Therapeutics, Inc. (OTCQB: BTHE). The full 60-page report is available on Crystal Research Associates' website at www.crystalra.com.
Boston Therapeutics Reports Corporate Update and Financial Results for the Fourth Quarter and Year Ended December 31, 2013
Marketwire - Mon Mar 17, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a leading developer of compounds that address diabetes using complex carbohydrate chemistry, reports its financial results for the fourth quarter and year ended December 31, 2013.
Boston Therapeutics to launch Phase II clinical study of BTI-320 in the US in Type 2 diabetes patients
M2 - Wed Mar 05, 6:16AM CST
Complex carbohydrate company Boston Therapeutics (OTCQB:BTHE) said on Tuesday that it will start clinical study of BTI-320 in the US upon Institutional Review Board (IRB) approval.
Boston Therapeutics to Initiate a Phase II Clinical Study of BTI-320 in U.S.
Marketwire - Tue Mar 04, 6:20AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company", an innovative developer of compounds that address diabetes using complex carbohydrate chemistry, has received Institutional Review Board (IRB) approval to initiate a clinical study of BTI-320 (previously named PAZ320) in the United States. The Company expects the trial to last for approximately three months. The U.S.-based trial is intended to mirror the Company's study of BTI-320 currently enrolling patients in France.
Boston Therapeutics Appoints Larry K. Ellingson, Former Chair of the American Diabetes Association, as Chair of Its Scientific Advisory Board
Marketwire - Tue Feb 25, 6:02AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company", an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has appointed Larry K. Ellingson as Chairman of its Scientific Advisory Board, effective immediately.
Boston Therapeutics Signs Agreement to Market SugarDown(R) in the U.S.
Marketwire - Tue Feb 11, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company", an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has signed a consulting agreement with Generosus Advisors, LLC and Fortified Management Group, LLC to market SugarDown(R) in the United States on a non-exclusive basis. The marketing effort will be conducted via the Help Now Network (HNN), a healthcare marketing company and its affiliates. SugarDown(R) is a dietary supplement that is indicated in its functional claims to support healthy blood sugar and has shown in clinical studies to reduce after meal sugar spikes.
Provide Good Service and 'Pirates' Will Go
All Africa Global Media - Fri Dec 20, 10:05AM CST
"What comes first is good service and customers follow. We cannot invert these natural laws of commerce to protect incompetent managers at the NRZ."
Boston Therapeutics Appoints Three to Management Positions
Marketwire - Tue Dec 10, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company", an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has appointed Edward Shea as Vice President Business Development, Tina M. Gagnon as Consulting Director of Finance, and Yael T. Bobruff, Ph.D. as Clinical Affairs Manager, effective immediately.
Boston Therapeutics, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
PR Newswire - Fri Dec 06, 1:12PM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) today announced its December 5th RetailInvestorConferences.com presentation is now available for on-demand viewing.
Boston Therapeutics Appoints Conroy Chi-Heng Cheng and S. Colin Neill to Board of Directors
Marketwire - Wed Dec 04, 11:48AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company", an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, appointed Conroy Chi-Heng Cheng and S. Colin Neill to its Board of Directors, effective immediately. Mr. Neill replaces Mr. Carl Lueders as chair of the Company's Audit Committee. Mr. Lueders left the Board to spend more time with his new business venture. In addition, the Company named Anthony D. Squeglia as Chief Financial Officer.
NYSE, OTC and Nasdaq Companies Webcast to Online Investors: December 5th at RetailInvestorConferences.com
PR Newswire - Tue Dec 03, 6:30AM CST
PR Newswire, BetterInvesting, and MUNCmedia today announced the agenda of the upcoming RetailInvestorConferences.com, the monthly online investor conference series. Individual investors, institutional investors and analysts are invited.
Boston Therapeutics Presents at the Elsevier Therapeutic Area Partnerships 2013 Conference in Boston on November 19
Marketwire - Mon Nov 18, 6:39AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company", an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, will be presenting at the Elsevier Therapeutic Area Partnerships ("TAP" 2013 Conference at The Hyatt Regency in Boston on Tuesday, November 19 from 2:15 pm to 3:05 pm ET within Track 4 (Cardiovascular/Metabolic Diseases).
Boston Therapeutics Exhibits at Obesity Week 2013 Conference
Marketwire - Thu Nov 14, 6:05AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company", an innovator developer of drugs that address diabetes using complex carbohydrate chemistry, will provide information about PAZ320, an investigational non-systemic chewable tablet, that when taken as an adjunctive therapy, helped patients with Type II diabetes manage the post meal elevation of their blood sugar in a Phase IIa clinical trial, at booth #127 at the inaugural Obesity Week 2013 Conference in Atlanta, Georgia, November 13 to 15.
Boston Therapeutics Reports Corporate Update and Financial Results for the Third Quarter and Nine Months Ended September 30, 2013
Marketwire - Wed Nov 13, 3:05PM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company", an innovator of drugs that address diabetes using complex carbohydrate chemistry, reports its corporate update and financial results for the three and nine months ended September 30, 2013.
Boston Therapeutics Enrolls Patients With Type 2 Diabetes in a Phase IIb Clinical Trial With PAZ320
Marketwire - Tue Nov 12, 6:01AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company", an innovator in designing drugs that address diabetes using complex carbohydrate chemistry, today began enrolling patients in a Phase IIb clinical study on PAZ320, a complex carbohydrate-based drug designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes.
Boston Therapeutics Inc concludes USD3.5m private placement
M2 - Tue Sep 10, 7:35AM CDT
Drug company Boston Therapeutics Inc (OTCQB:BTHE) revealed on Monday the completion of a private placement of common stock and warrants for total gross proceeds of USD3.5m.
Boston Therapeutics Closes on Approximately $3.5 Million in Private Placement of Common Stock and Warrants
Marketwire - Mon Sep 09, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company", a developer of drugs based on complex carbohydrate chemistry to treat diabetes and inflammatory diseases, has closed on total gross proceeds of approximately $3.5 million to date from the private placement offering of common stock and warrants to existing and new accredited investors.
Boston Therapeutics Signs Agreement With Patheon to Manufacture Pharmaceutical-Grade BTI-320 Tablets
Marketwire - Wed May 07, 5:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a clinical stage developer of innovator compounds that address diabetes and inflammatory diseases using complex carbohydrate chemistry, along with its Hong Kong-based strategic partner Advance Pharmaceutical Company, have together signed an agreement with pharmaceutical manufacturing company Patheon Inc. to manufacture pharmaceutical-grade tablets of the company's lead product candidate BTI-320, a compound designed to reduce post-meal elevation of blood glucose.
Boston Therapeutics to manufacture lead blood glucose product candidate BTI-320 in partnership with Advance Pharmaceutical Company and Patheon
M2 - Tue May 06, 7:54AM CDT
Carbohydrate chemistry company Boston Therapeutics (OTCQB:BTHE) reported on Tuesday the launch of an agreement to manufacture its pharmaceutical-grade tablets of its lead product candidate BTI-320 in partnership with its Hong Kong-based strategic partner Advance Pharmaceutical Company and Patheon.
Boston Therapeutics to Present Late-Breaking Poster on Mechanism of Action for BTI-320 at AACE Annual Congress in Las Vegas on May 14-18
Marketwire - Tue Apr 29, 5:15AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a clinical stage developer of innovative compounds that address diabetes and inflammatory diseases using complex carbohydrate chemistry, will present a late-breaking poster relating to its lead product candidate, BTI-320, at the American Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific and Clinical Congress at the Paris Las Vegas Hotel in Las Vegas, Nevada, May 14-18.
Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Boston Therapeutics, Inc.
Marketwire - Thu Mar 27, 8:32AM CDT
Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO) on Boston Therapeutics, Inc. (OTCQB: BTHE). The full 60-page report is available on Crystal Research Associates' website at www.crystalra.com.
Boston Therapeutics Reports Corporate Update and Financial Results for the Fourth Quarter and Year Ended December 31, 2013
Marketwire - Mon Mar 17, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a leading developer of compounds that address diabetes using complex carbohydrate chemistry, reports its financial results for the fourth quarter and year ended December 31, 2013. Boston Therapeutics to launch Phase II clinical study of BTI-320 in the US in Type 2 diabetes patients
M2 - Wed Mar 05, 6:16AM CST
Complex carbohydrate company Boston Therapeutics (OTCQB:BTHE) said on Tuesday that it will start clinical study of BTI-320 in the US upon Institutional Review Board (IRB) approval.
Boston Therapeutics to Initiate a Phase II Clinical Study of BTI-320 in U.S.
Marketwire - Tue Mar 04, 6:20AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, an innovative developer of compounds that address diabetes using complex carbohydrate chemistry, has received Institutional Review Board (IRB) approval to initiate a clinical study of BTI-320 (previously named PAZ320) in the United States. The Company expects the trial to last for approximately three months. The U.S.-based trial is intended to mirror the Company's study of BTI-320 currently enrolling patients in France. Boston Therapeutics Appoints Larry K. Ellingson, Former Chair of the American Diabetes Association, as Chair of Its Scientific Advisory Board
Marketwire - Tue Feb 25, 6:02AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has appointed Larry K. Ellingson as Chairman of its Scientific Advisory Board, effective immediately. Boston Therapeutics Signs Agreement to Market SugarDown(R) in the U.S.
Marketwire - Tue Feb 11, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has signed a consulting agreement with Generosus Advisors, LLC and Fortified Management Group, LLC to market SugarDown(R) in the United States on a non-exclusive basis. The marketing effort will be conducted via the Help Now Network (HNN), a healthcare marketing company and its affiliates. SugarDown(R) is a dietary supplement that is indicated in its functional claims to support healthy blood sugar and has shown in clinical studies to reduce after meal sugar spikes. Provide Good Service and 'Pirates' Will Go
All Africa Global Media - Fri Dec 20, 10:05AM CST
"What comes first is good service and customers follow. We cannot invert these natural laws of commerce to protect incompetent managers at the NRZ."
Boston Therapeutics Appoints Three to Management Positions
Marketwire - Tue Dec 10, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has appointed Edward Shea as Vice President Business Development, Tina M. Gagnon as Consulting Director of Finance, and Yael T. Bobruff, Ph.D. as Clinical Affairs Manager, effective immediately. Boston Therapeutics, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
PR Newswire - Fri Dec 06, 1:12PM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) today announced its December 5th RetailInvestorConferences.com presentation is now available for on-demand viewing.
Boston Therapeutics Appoints Conroy Chi-Heng Cheng and S. Colin Neill to Board of Directors
Marketwire - Wed Dec 04, 11:48AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, appointed Conroy Chi-Heng Cheng and S. Colin Neill to its Board of Directors, effective immediately. Mr. Neill replaces Mr. Carl Lueders as chair of the Company's Audit Committee. Mr. Lueders left the Board to spend more time with his new business venture. In addition, the Company named Anthony D. Squeglia as Chief Financial Officer. NYSE, OTC and Nasdaq Companies Webcast to Online Investors: December 5th at RetailInvestorConferences.com
PR Newswire - Tue Dec 03, 6:30AM CST
PR Newswire, BetterInvesting, and MUNCmedia today announced the agenda of the upcoming RetailInvestorConferences.com, the monthly online investor conference series. Individual investors, institutional investors and analysts are invited.
Boston Therapeutics Presents at the Elsevier Therapeutic Area Partnerships 2013 Conference in Boston on November 19
Marketwire - Mon Nov 18, 6:39AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, will be presenting at the Elsevier Therapeutic Area Partnerships ("TAP" 2013 Conference at The Hyatt Regency in Boston on Tuesday, November 19 from 2:15 pm to 3:05 pm ET within Track 4 (Cardiovascular/Metabolic Diseases). Boston Therapeutics Exhibits at Obesity Week 2013 Conference
Marketwire - Thu Nov 14, 6:05AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, an innovator developer of drugs that address diabetes using complex carbohydrate chemistry, will provide information about PAZ320, an investigational non-systemic chewable tablet, that when taken as an adjunctive therapy, helped patients with Type II diabetes manage the post meal elevation of their blood sugar in a Phase IIa clinical trial, at booth #127 at the inaugural Obesity Week 2013 Conference in Atlanta, Georgia, November 13 to 15. Boston Therapeutics Reports Corporate Update and Financial Results for the Third Quarter and Nine Months Ended September 30, 2013
Marketwire - Wed Nov 13, 3:05PM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, an innovator of drugs that address diabetes using complex carbohydrate chemistry, reports its corporate update and financial results for the three and nine months ended September 30, 2013. Boston Therapeutics Enrolls Patients With Type 2 Diabetes in a Phase IIb Clinical Trial With PAZ320
Marketwire - Tue Nov 12, 6:01AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, an innovator in designing drugs that address diabetes using complex carbohydrate chemistry, today began enrolling patients in a Phase IIb clinical study on PAZ320, a complex carbohydrate-based drug designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes. Boston Therapeutics Inc concludes USD3.5m private placement
M2 - Tue Sep 10, 7:35AM CDT
Drug company Boston Therapeutics Inc (OTCQB:BTHE) revealed on Monday the completion of a private placement of common stock and warrants for total gross proceeds of USD3.5m.
Boston Therapeutics Closes on Approximately $3.5 Million in Private Placement of Common Stock and Warrants
Marketwire - Mon Sep 09, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of drugs based on complex carbohydrate chemistry to treat diabetes and inflammatory diseases, has closed on total gross proceeds of approximately $3.5 million to date from the private placement offering of common stock and warrants to existing and new accredited investors. 
